Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML

9 May 2013

Abstract excerpt

Mutations of the NPM1 gene (NPM1mut) are among the most common genetic alterations in acute myeloid leukemia and are suitable for minimal residual disease detection. We retrospectively investigated the prognostic impact of NPM1mut-based minimal residual disease detection from bone marrow for development of relapse by using a newly developed real-time polymerase chain reaction based on locked nucleic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Retinoids in leukemia and cellular processes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23656730
DOI: 10.1182/blood-2012-10-461749

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AMLPMID 23656730Read ↗

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.Semantic proximity Read ↗

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.Semantic proximity Read ↗

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.Semantic proximity Read ↗

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.Semantic proximity Read ↗

Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.Semantic proximity Read ↗

NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia.Semantic proximity Read ↗

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.Semantic proximity Read ↗

Genetic biomarkers identify a subgroup of high-risk patients within low-risk NPM1-mutated acute myeloid leukemia.Semantic proximity Read ↗

NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapseSemantic proximity Read ↗

Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML.Semantic proximity Read ↗

High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemiaSemantic proximity Read ↗

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.